2025Year9Month9Day,Boston Scientific (Boston Scientific，NYSE: BSX) Announced to8800Million USD (approximately RMB6.3USD 100 Million) Cash Acquisition of Medical Technology CompanyElutia（NASDAQ: ELUT) ofEluProAndCanGarooBiological Membrane Technology.This transaction is expected to be completed on2025Completed in the fourth quarter of the year.Marks Boston Scientific's official entry into the biological envelope field, directly challenging Medtronic's monopoly in this niche market.

ElutiaFormerly known asAziyo Biologics, at2015Aziyo Biologics, Inc., registered in Delaware, is a commercial-stage company focused on regenerative medicine. With drug-eluting bio-matrix technology at its core, it provides innovative protective solutions for implantable medical devices while expanding into women's health and cardiovascular fields, committed to improving surgical outcomes and clinical results for patients.2023Year9Renamed inElutia, to reflect its strategic focus shifting towards the development and commercialization of drug-eluting biologics technology.

Through this acquisition, Boston Scientific Corporation will obtainEluProAndCanGarooBiological Membrane Products：

• EluPro: An antibiotic-eluting biological wrap platform, at2024Year6Monthly AcquisitionFDAApproved, reducing the risk of postoperative infection by locally releasing antimicrobial agents.EluProAlsoIs the first to obtainFDAApproved Drug-Eluting Coating。Its advantage lies in compatibility with a variety of devices, including cardiac rhythm management devices and neuromodulation equipment. Clinical data shows,EluProCan significantly reduce complications such as bacterial colonization, device migration, and skin erosion.

  
  

• CanGaroo: Using porcine small intestinal submucosal extracellular matrix (SIS-ECM) materials not only provide stable physical support for implantable devices but also improve the tissue healing environment through bio-inductive properties. Studies have confirmed,SIS-ECMCan enhance regulatory signals (such asVEGF-A) release, reducing long-term fibrosis and inflammatory responses, creating a healthier microenvironment for the device.

After the transaction is completed,ElutiaWill Obtain8800Million USD in cash, mainly used for repaying debts, resolving historical litigation, and advancing the next-generation product.NXT-41xR&D.NXT-41xIt is an antibacterial biological matrix for breast reconstruction surgery, targeting markets with high infection risks and clear clinical needs, and is expected to become a new growth point for the company.。

ElutiaExpressed that, through divestitureCRMIn the field of biological coatings, the company can focus its resources on more promising differentiated products, avoiding direct competition with large multinational corporations in high-cost market promotions.

ElutiaChief Executive Officer Randy Mills (Randy Mills")" indicates: "EluProThe successful launch has proven the scalability potential of our drug-eluting biological platform.This transaction will unlock resources to advance the next generation of antimicrobial biological matrices for breast reconstruction.NXT-41xCommercialization, Targeting15The U.S. market worth billions of dollars."

Boston Scientific has developed a wide range of implantable devices, including leading defibrillators and pacemakers. The company's cardiology pageLinkedInMedtronic announced the transaction, stating thatElutiaThe product can further enhance its ability to protect patients. Senior Vice President and Global Chief Medical OfficerKen SteinSaid that despite significant advances in cardiac implantable electronic device therapy, complications such as bacterial colonization, migration, and skin erosion may still occur. Incorporating antibiotic-elutingEluProBiological capsule andCanGarooThe capsule is an important step for the company to address these challenges.EluPro BioEnvelopeCombining antibiotic delivery with tissue engineering helps form a regenerative pocket within the patient's own tissue, reducing postoperative complications.

BTIGAnalystMarie Thibault、Sam EiberAndAlexandra PangPoint out,ElutiaThe market opportunity for technology in the United States is approximately6Billion US dollars.Boston Scientific Corporation andElutiaAlready has a partnership in the distribution of biological membrane products, withTYRXAbsorbable Antibacterial Envelope,Boston Scientific Corporation has been able to manage heart rhythms (CRM) field to compete with Medtronic. This acquisition makes Boston Scientific a direct competitor of Medtronic in the biologic envelope field, and analysts believeEluProBiological envelope and MedtronicTYRXCompared to bags, it may have clinical and handling advantages, and Boston Scientific Corporation is expectedInProduct SalesAlso highly competitive in this aspect。Although there may be other interested acquirers, given Boston Scientific andElutiaThe established close partnership is expected to deter additional bidders.

Marie ThibaultAs mentioned in the research report,ElutiaIn2025The Second Quarter of the Year (2Q25) ofBioenvelopeRevenue is350Million US dollars, of whichEluProContributed two-thirds of the sales. This transaction was conducted in cash and is expected to have a positive impact on Boston Scientific's financial condition and operations. The specific effects will depend on the integration outcomes and market feedback after the completion of the transaction, which remain to be further observed.

This acquisition reflects the deep-seated changes in the cardiac rhythm management sector. With the risk of postoperative infection associated with implanted devices (approximately1%-2%) are becoming increasingly severe (reoperation, increased mortality, soaring hospitalization costs), and anti-infection measures are transitioning from optional add-ons to standard configurations. Compared with traditional synthetic materials,EluProCombining drug release with tissue friendliness, it is considered by clinical experts to have more advantages in device stability, ease of removal, and infection control.。

Boston ScientificElutiaThe acquisition of bio-envelope technology is not only the transfer of a single asset, but also a sign that the rhythm management track is evolving from "device-oriented" to "overall ecological orientation." With "biological materials+"Drug Release" Combination Solution Becomes a New Trend in the Industry,Instrument之家 will closely followThis DealTo the marketCompetitive LandscapeThe Impact。